Ovid Therapeutics Inc.
OVIDHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ovid Therapeutics Inc. focuses on Biotechnology services and products. Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the. Valued at $421.8M, OVID is a small-cap name in its sector. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Market Cap
$421.8M
Beta
0.23
P/E (TTM)
—
P/E (Fwd)
-5.89
EPS (TTM)
$-0.22
EPS (Fwd)
$-0.37
ROE
-26.0%
ROA
-23.5%
Cash
$117.2M
Total Debt
$12.7M
Free CF
-$33.1M
52W Change
35.0%
Annual Financials
Cash vs Debt
Where OVID stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, OVID finished 14.90% below its 150-day moving average ($2.55) and 6.87% below its 200-day moving average ($2.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OVID overbought or oversold?
At the October 20, 2026 close, OVID's RSI(14) was 28.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $117.2M in cash comfortably exceeding the $12.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$33.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.5M (2022) to $7.3M (2025), reflecting a 383% increase over the period.
OVID's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OVID.